Overview

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborator:
Celgene Corporation
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Cetuximab
Paclitaxel